BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC 50 of 1 nM and dissociation constant ( K d ) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research.